End-of-day quote
2026-09-04
5-day change
1st Jan Change
85.10 NOK
+0.12%
+0.12%
-14.90%
Market Cap
513M
55.19M
47.49M
44.68M
40.82M
76.36M
5.21B
76.56M
528M
205M
2.67B
207M
203M
8.61B
P/E 2023 *
-
P/E 2024
3.26x Enterprise Value
264M
28.43M
24.46M
23.02M
21.03M
39.33M
2.68B
39.44M
272M
106M
1.38B
107M
104M
4.44B
EV / Sales 2023
-1.24x
EV / Sales 2024
0.4x Free-Float
6.26%
Yield 2023 *
-
Yield 2024
32.5%
Day Week Month
Close Mountain
06-16
Norda ASA announces Annual dividend, payable on June 25, 2026
CI
25-05-12
Norda ASA announces Annual dividend, payable on May 22, 2025
CI
25-05-05
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2024
CI
23-10-31
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2022
CI
22-06-15
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
21-06-20
Norda Asa Reports Earnings Results for the Full Year Ended December 31, 2020
CI
13-05-22
Norda ASA Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2013
CI
13-04-09
Norda ASA Reports Unaudited Net Debt Results as of December 31, 2012
CI
13-04-09
Norda ASA Appoints Scient Frode Westvold as CEO
CI
13-02-28
Norda ASA Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2012
CI
12-10-31
Norda ASA Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012
CI
12-10-12
Norda ASA Obtains NOK 35 Million Line of Credit from a Norwegian Bank
CI
12-08-29
Norda ASA Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2012
CI
1 day +0.12%
1 week +0.12%
Current month +0.12%
1 month -1.50%
3 months -1.50%
Current year -14.90%
1 week
85.1
85.1
1 month
85
85.1
Current year
81
86.4
1 year
81
100
3 years
41
100
5 years
41
100
10 years
8
100
Manager
Title Age Since
Chief Executive Officer
-
2013-04-07
Director
Title Age Since
Chairman
54
2014-01-30
Director/Board Member
68
2013-06-19
Director/Board Member
-
-
2023 2024 Net sales
86.92M
9.35M
8.04M
7.57M
6.91M
12.93M
883M
12.97M
89.43M
34.7M
453M
35.1M
34.34M
1.46B
372M
39.99M
34.41M
32.38M
29.58M
55.33M
3.78B
55.48M
383M
148M
1.94B
150M
147M
6.24B
Net income
31.17M
3.35M
2.88M
2.71M
2.48M
4.64M
317M
4.65M
32.07M
12.45M
162M
12.59M
12.31M
523M
126M
13.54M
11.66M
10.97M
10.02M
18.74M
1.28B
18.79M
130M
50.28M
656M
50.86M
49.75M
2.11B
Net Debt
-311M
-33.47M
-28.8M
-27.1M
-24.76M
-46.31M
-3.16B
-46.44M
-320M
-124M
-1.62B
-126M
-123M
-5.22B
-249M
-26.76M
-23.03M
-21.66M
-19.79M
-37.02M
-2.53B
-37.12M
-256M
-99.34M
-1.3B
-100M
-98.29M
-4.18B
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-6pm CET
×
DAILY FREE LIMIT REACHED
To continue browsing, Sign up!
Personal watchlists and screeners
Access the "Discovery" Stock Screener (covering 30,000 companies)
Create your free account
Become a member and join over 1 million active investors
Already have an account?
Log in
Select your edition
All financial news and data tailored to specific country editions